{"contentid": 488502, "importid": NaN, "name": "UK\u00e2\u0080\u0099s MHRA approves Xeris\u00e2\u0080\u0099 Ogluo", "introduction": "The UK\u00e2\u0080\u0099s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus, said the drug\u00e2\u0080\u0099s developer, Xeris Pharmaceuticals.", "content": "<p>The UK&rsquo;s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus, the drug&rsquo;s developer, Xeris Pharmaceuticals (Nasdaq: XERS), has announced.</p>\n<p>The company&rsquo;s shares were up 3.4% at $4.00 pre-market.</p>\n<p>In February, the European Commission (EC) approved Ogluo. As the EC decision was received after the end of the Brexit transition period, Xeris was required to complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by MHRA was required. The marketing authorization is valid in the UK and all 27 countries of the European Union, Iceland, Norway, and Liechtenstein.</p>\n<h2><strong>Seeking commercialization partners</strong></h2>\n<p>As previously stated, the Company is actively seeking a partner to commercialize Ogluo in the UK, European Union, and other regions, with a targeted fourth quarter 2021 launch in select EU countries.</p>\n<p>Under the trade names Gvoke PFS and Gvoke HypoPen, Xeris&rsquo; glucagon injections, were approved by the US Food and Drug Administration in September 2019.</p>\n<p>By that time, Eli Lilly (NYSE: LLY) was already busy rolling out its nasal powder product, Baqsimi (glucagon), which became the first US FDA approved needle-free glucagon therapy in July. Like Gvoke, Baqsimi can be used to treat emergency episodes of hypoglycemia.</p>", "date": "2021-04-30 10:37:00", "meta_title": "UK\u00e2\u0080\u0099s MHRA approves Xeris\u00e2\u0080\u0099 Ogluo", "meta_keywords": "Xeris, Ogluo, Hypoglycemia, Approval, MHRA", "meta_description": "UK\u00e2\u0080\u0099s MHRA approves Xeris\u00e2\u0080\u0099 Ogluo", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 10:36:30", "updated": "2021-04-30 10:42:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/uk-s-mhra-approves-xeris-ogluo", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "xeris_pharmaceuticals_big.jpg", "image2id": "xeris_pharmaceuticals_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Diabetes", "topic_tag": "Focus On, Medicines and Healthcare products Regulatory Agency (MHRA), Regulation", "geography_tag": "UK, USA", "company_tag": "Xeris Pharmaceuticals", "drug_tag": "Gvoke, Ogluo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 10:37:00"}